Hans P Hartung

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. doi request reprint Immune regulation of multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany Electronic address
    Handb Clin Neurol 122:3-14. 2014
  2. doi request reprint Interleukin 17F level and interferon β response in patients with multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine Universitat, Dusseldorf, Germany
    JAMA Neurol 70:1017-21. 2013
  3. pmc The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
    Petra D Cravens
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9036, USA
    J Neuroinflammation 10:67. 2013
  4. pmc Effects of dimethyl fumarate on neuroprotection and immunomodulation
    Philipp Albrecht
    Department of Neurology, Heinrich Heine University Dusseldorf, Medical Faculty, Dusseldorf 40225, Germany
    J Neuroinflammation 9:163. 2012
  5. pmc In vitro neuronal network activity in NMDA receptor encephalitis
    Sabine U Jantzen
    Department of Neurology, LVR Klinikum Duesseldorf, Bergische Landstrasse 2, 40629, Duesseldorf, Germany
    BMC Neurosci 14:17. 2013
  6. pmc Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
    Ralph H B Benedict
    Buffalo General Medical Center, Department of Neurology, Suite E2, 100 High Street, Buffalo, NY 14203, USA
    BMC Neurol 12:55. 2012
  7. pmc An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess
    Philipp Albrecht
    Department of Neurology, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    BMC Neurol 12:133. 2012
  8. doi request reprint Treatment of chronic inflammatory demyelinating polyradiculoneuropathy
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany Electronic address
    Handb Clin Neurol 115:415-27. 2013
  9. doi request reprint [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience]
    H P Hartung
    Neurologische Klinik im UKD, Medizinische Fakultat, Heinrich Heine Universitat, Moorenstr 5, 40225 Dusseldorf, Deutschland
    Nervenarzt 84:679-704. 2013
  10. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012

Detail Information

Publications96

  1. doi request reprint Immune regulation of multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany Electronic address
    Handb Clin Neurol 122:3-14. 2014
    ..This ultimately leads to demyelination and axonal damage. This chapter focuses on the role of T and B lymphocytes in the immunopathogenesis of MS. ..
  2. doi request reprint Interleukin 17F level and interferon β response in patients with multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine Universitat, Dusseldorf, Germany
    JAMA Neurol 70:1017-21. 2013
    ..High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis...
  3. pmc The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
    Petra D Cravens
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9036, USA
    J Neuroinflammation 10:67. 2013
    ..In contrast, IL-17 transcripts could not be detected in adult or neonate CNS in this EAE model, and neither adult nor neonate donor CD4+ T cells expressed IL-17 at the time of adoptive transfer...
  4. pmc Effects of dimethyl fumarate on neuroprotection and immunomodulation
    Philipp Albrecht
    Department of Neurology, Heinrich Heine University Dusseldorf, Medical Faculty, Dusseldorf 40225, Germany
    J Neuroinflammation 9:163. 2012
    ..These effects are presumed to originate from a combination of immunomodulatory and neuroprotective mechanisms. We aimed to clarify whether neuroprotective concentrations of dimethyl fumarate have immunomodulatory effects...
  5. pmc In vitro neuronal network activity in NMDA receptor encephalitis
    Sabine U Jantzen
    Department of Neurology, LVR Klinikum Duesseldorf, Bergische Landstrasse 2, 40629, Duesseldorf, Germany
    BMC Neurosci 14:17. 2013
    ..It predominantly occurs in young women and is associated in 59% with an ovarian teratoma...
  6. pmc Brief International Cognitive Assessment for MS (BICAMS): international standards for validation
    Ralph H B Benedict
    Buffalo General Medical Center, Department of Neurology, Suite E2, 100 High Street, Buffalo, NY 14203, USA
    BMC Neurol 12:55. 2012
    ..At this time, preliminary studies are underway in a number of countries as we move forward with this international assessment tool for cognition in MS...
  7. pmc An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess
    Philipp Albrecht
    Department of Neurology, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    BMC Neurol 12:133. 2012
    ....
  8. doi request reprint Treatment of chronic inflammatory demyelinating polyradiculoneuropathy
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany Electronic address
    Handb Clin Neurol 115:415-27. 2013
    ..In this chapter an overview of the currently used drugs in the treatment of CIDP patients is given and some important and controversial issues that arise in the context of care for CIDP patients are discussed. ..
  9. doi request reprint [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience]
    H P Hartung
    Neurologische Klinik im UKD, Medizinische Fakultat, Heinrich Heine Universitat, Moorenstr 5, 40225 Dusseldorf, Deutschland
    Nervenarzt 84:679-704. 2013
    ....
  10. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012
    ..Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs...
  11. pmc Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Sven Jarius
    Neurocure, Charite University Medicine Berlin, Berlin, Germany
    J Neuroinflammation 9:14. 2012
    ..However, little is known so far about the clinical impact of AQP4-Ab seropositivity...
  12. doi request reprint [Guillain-Barré syndrome after exposure to influenza]
    H P Hartung
    Neurologische Klinik, Heinrich Heine Universitat, Moorenstr 5, 40225 Dusseldorf, Deutschland
    Nervenarzt 83:714-30. 2012
    ..Vaccination against influenza is associated with a very low risk for the occurrence of GBS. In contrast infection with influenza may play a more important role as a triggering factor for GBS than previously assumed...
  13. pmc Niche-dependent development of functional neuronal networks from embryonic stem cell-derived neural populations
    Sebastian Illes
    Department of Neurology, Heinrich Heine University, Moorenstr, 5, Dusseldorf 40225, Germany
    BMC Neurosci 10:93. 2009
    ..However, the ability of these different ES cell-derived immature neural cell populations to generate functional neuronal networks has not been assessed so far...
  14. doi request reprint [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy]
    H P Hartung
    Neurologische Klinik, Heinrich Heine Universitat, Moorenstrasse 5, 40225, Dusseldorf, Deutschland
    Nervenarzt 80:1143-4, 1146-8, 1150-3. 2009
    ..The risk of PML in patients with MS needs to be continually monitored and should be reduced with all means available to ensure optimal outcome...
  15. ncbi request reprint High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
    Hans Peter Hartung
    Heinrich Heine University, Department of Neurology, Moorenstreet 5, D 40225 Dusseldorf, Germany
    Expert Opin Pharmacother 10:291-309. 2009
    ....
  16. doi request reprint [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]
    H P Hartung
    Neurologische Klinik, Heinrich Heine Universitat, Moorenstrasse 5, Dusseldorf
    Nervenarzt 80:1462-72. 2009
    ..Ongoing clinical studies are investigating the safety, tolerability and efficacy of atacicept in patients with MS, SLE and RA...
  17. ncbi request reprint Early treatment and dose optimisation BENEFIT and BEYOND
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine Universitat, Moorenstrasse 5, 40225 Dusseldorf, Germany
    J Neurol 252:iii44-iii50. 2005
    ..A third treatment arm will provide a comparison with glatiramer acetate 20mg subcutaneously once daily...
  18. doi request reprint Advances in the understanding of the mechanism of action of IVIg
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine University, Moorenstr 5, 40225, Duesseldorf, Germany
    J Neurol 255:3-6. 2008
    ..In conclusion, IVIg has numerous modes of action, which culminate in the down-regulation of the immune response; many of which may be relevant to neuromuscular disorders and immune neuropathies...
  19. ncbi request reprint Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report
    Hans P Hartung
    Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
    J Neurol 254:827-37. 2007
    ....
  20. ncbi request reprint Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis
    Hans Peter Hartung
    Neurologische Klinik, Heinrich Heine Universitat Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany
    J Neurol 252:v30-7. 2005
    ..All have been shown to reduce the number of gadolinium-enhancing T1 lesions observed with magnetic resonance imaging, an index of acute inflammatory invasion of the central nervous system...
  21. ncbi request reprint Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference
    H P Hartung
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Eur J Neurol 12:588-601. 2005
    ..This article summarizes the opinions of the expert panel on a number of key issues raised at the meeting...
  22. ncbi request reprint What do we know about the mechanism of action of disease-modifying treatments in MS?
    Hans Peter Hartung
    Heinrich Heine University, Moorenstrasse 4, 40225 Duesseldorf, Germnay
    J Neurol 251:v12-v29. 2004
    ..Further increases in our understanding of the pathogenesis of MS are likely to assist in the identification of new targets for disease-modifying therapies and in the optimisation of current treatments....
  23. pmc Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology
    H P Hartung
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Clin Exp Immunol 158:23-33. 2009
    ..This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact...
  24. ncbi request reprint Assessment and management of neutralizing antibodies in patients with multiple sclerosis
    Hans Peter Hartung
    Heinrich Heine University, Department of Neurology, Dusseldorf, Germany
    J Neurol 251:II40-2. 2004
    ..This article summarizes the content of this supplement, discusses issues related to measuring NAbs in clinical practice, and gives practical alternatives for managing MS in patients who develop NAbs during IFNbeta therapy...
  25. doi request reprint Development of oral cladribine for the treatment of multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine University, Moorenstr 5, 40225 Dusseldorf, Germany
    J Neurol 257:163-70. 2010
    ..Preliminary results of the 96-week, double-blind, randomized, placebo-controlled, multicenter CLARITY (CLAdRIbine Tablets Treating MS OrallY) study are encouraging and provide the first complete phase III data on an oral DMD for MS...
  26. doi request reprint [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis]
    H P Hartung
    Neurologische Klinik, Heinrich Heine Universitat, Moorenstrasse 5, Dusseldorf, Germany
    Nervenarzt 81:194-202. 2010
    ..They clearly show that oral cladribine reduces relapse rate, disability progression and disease activity and burden as evidenced by MRI...
  27. doi request reprint Principles of a new treatment algorithm in multiple sclerosis
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine University Medical School, Dusseldorf, Germany
    Expert Rev Neurother 11:351-62. 2011
    ..This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents...
  28. doi request reprint Novel treatment for immune neuropathies on the horizon
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany MRC Neuromuscular Disease Centre, Institute of Neurology, University College London, London, UK
    J Peripher Nerv Syst 16:75-83. 2011
    ..Here, we review the available clinical data as well as the scientific rationale and expected benefits and risks for these strategies...
  29. ncbi request reprint Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
    Hans Peter Hartung
    Department of Neurology, Heinrich Heine Universitat, Dusseldorf, Germany
    Lancet 360:2018-25. 2002
    ..Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open-label studies prompted this randomised trial of mitoxantrone in such patients...
  30. doi request reprint Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome
    H P Hartung
    Department of Neurology, Heinrich Heine Universitat, Dusseldorf 40225, Germany
    Neurology 77:835-43. 2011
    ..To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b)...
  31. ncbi request reprint Current disease-modifying therapies in multiple sclerosis
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Semin Neurol 23:133-46. 2003
    ..The clinical utility of disease-modifying agents in MS will be reviewed with respect to the anti-inflammatory, immunomodulatory, and immunosuppressive treatments that are currently available. Symptomatic therapies will not be considered...
  32. ncbi request reprint The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis
    Heinz Wiendl
    Department of Neurology, University of Tubingen, Hoppe Seyler Strasse 3, Tubingen, D 72076, Germany
    J Neuroimmunol 140:177-87. 2003
    ..In MS patients we demonstrate the functionality of the ICOS costimulatory pathway. Potential implications of ICOSL/ICOS interactions for MS immunopathogenesis are discussed...
  33. ncbi request reprint Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve
    Wei Hu
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Dusseldorf, Germany
    Neurology 61:1774-9. 2003
    ..To investigate the expression of cyclo-oxygenases (COX), key enzymes in propagating inflammatory responses by converting arachidonic acid to prostaglandins, in inflammatory demyelinating disorders of the peripheral nervous system (PNS)...
  34. ncbi request reprint Treatment and treatment trials in multiple sclerosis
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
    Curr Opin Neurol 20:286-93. 2007
    ..This review focuses on advances in current and novel treatment approaches in multiple sclerosis...
  35. ncbi request reprint Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis
    Meike Mitsdoerffer
    Department of Neurology, University of Tubingen, Hoppe Seyler Strasse 3, D 72076 Tubingen, Germany
    J Neuroimmunol 159:155-64. 2005
    ..We conclude that some desirable immune-modulatory effects of INF-beta might be accomplished via the upregulation of the immune-tolerogenic molecule HLA-G...
  36. ncbi request reprint Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis
    Tea Kopadze
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Dusseldorf, Germany
    Arch Neurol 63:1572-8. 2006
    ..Mitoxantrone hydrochloride reduces progression of disability and clinical exacerbations in patients with multiple sclerosis. Its precise mode of action is unclear...
  37. ncbi request reprint Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS
    Hans Jörg Habisch
    Department of Neurology, University of Ulm, D89081 Ulm, Germany
    Exp Neurol 206:288-95. 2007
    ..In conclusion, the effects of COP-1 in the applied hybrid strain displaying a faster disease progression were less pronounced than in the earlier tested inbred strain of ALS mice...
  38. ncbi request reprint Chronic inflammatory demyelinating polyneuropathy
    Hubertus Köller
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    N Engl J Med 352:1343-56. 2005
  39. ncbi request reprint Immune circuitry in the peripheral nervous system
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Curr Opin Neurol 19:437-45. 2006
    ..Specifically, interactions of the immune system with cellular and extracellular components within peripheral nerve and immune functions of tissue-resident endoneurial macrophages and Schwann cells will be discussed...
  40. ncbi request reprint New immunopathologic insights into multiple sclerosis
    Bernhard Hemmer
    Department of Neurology, Heinrich Heine Universitat, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Curr Neurol Neurosci Rep 3:246-55. 2003
    ..We review the role of the immune system for the manifestation and evolution of MS and discuss different pathogenetic concepts. We conclude with an outlook on future strategies to identify the cause of MS...
  41. ncbi request reprint The immunocompetence of Schwann cells
    Gerd Meyer zu Horste
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Muscle Nerve 37:3-13. 2008
    ..This review summarizes current knowledge on the interaction of Schwann cells with the immune system, which is involved in diseases of the peripheral nervous system...
  42. ncbi request reprint Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system
    Martin Kurz
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Duesseldorf, Germany
    J Peripher Nerv Syst 10:311-8. 2005
    ..Our findings indicate that ADAM-17 is upregulated during EAN and expressed in nerves of GBS patients and thus may contribute to the pathogenesis of inflammatory demyelination of the PNS...
  43. pmc Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide
    Vsevolod Smolianov
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    J Neuroinflammation 8:59. 2011
    ..These findings might indicate a mechanism by which systemic infections and the microbial stimuli associated with them may influence already existing CNS autoimmune pathology...
  44. ncbi request reprint Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Bernhard Hemmer
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Ann Neurol 62:314-26. 2007
    ..Future treatments will likely need both to target inflammation and to focus on promotion of neuroprotection and repair. In this review, we discuss the most promising therapeutic approaches for MS currently in the pipeline...
  45. doi request reprint The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
    Fabian Zohren
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Blood 111:3893-5. 2008
    ..001), including pluripotent cells in colony-forming assays. This mobilizing ability of natalizumab might be useful for patients with poor response to granulocyte colony-stimulating factor (G-CSF)-based protocols...
  46. doi request reprint Plasma exchange in immune-mediated neuropathies
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Curr Opin Neurol 21:547-54. 2008
    ..Plasma exchange is frequently used for treatment of immune-mediated neuropathies. Here, we review the current value of plasma exchange in the treatment of different forms of immune-mediated neuropathies and discuss latest developments...
  47. doi request reprint The clinical value of therapeutic plasma exchange in multifocal motor neuropathy
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University of Dusseldorf, Germany
    J Neurol Sci 271:34-9. 2008
    ..We set out to elucidate possible reasons for this apparent contradiction...
  48. ncbi request reprint Mitoxantrone (Novantrone) in multiple sclerosis: new insights
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Expert Rev Neurother 4:17-26. 2004
    ....
  49. doi request reprint Word deafness as a cortical auditory processing deficit: a case report with MEG
    Silke Jörgens
    Department of Neurology, University Hospital, Dusseldorf, Germany
    Neurocase 14:307-16. 2008
    ..We conclude that auditory processing is disturbed at long latency ranges following the N100, which may result in the clinical presentation of pure word deafness...
  50. ncbi request reprint Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10
    Bernd C Kieseier
    Department of Neurology, Karl Franzens University, Graz, Austria
    Brain 125:823-34. 2002
    ..Our results imply a pathogenic role for specific chemokine receptors and IP-10 in the genesis of inflammatory demyelinating neuropathies...
  51. doi request reprint Intravenous immunoglobulins in the treatment of immune neuropathies
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
    Curr Opin Neurol 21:555-62. 2008
    ..The aim of this review is to describe the value of high-dose polyclonal intravenous immunoglobulins as a treatment option in autoimmune disorders affecting the peripheral nervous system...
  52. ncbi request reprint Bimanual recoupling by visual cueing in callosal disconnection
    Rudiger J Seitz
    Department of Neurology, University Hospital Dusseldorf, Dusseldorf, Germany
    Neurocase 10:316-25. 2004
    ..The data suggest that the visually cued movements of both hands were recoupled by action of a bihemispheric motor network...
  53. ncbi request reprint Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth
    Patrick Küry
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    FASEB J 19:398-400. 2005
    ..Therefore, OPN expression by lesion-associated macrophages may contribute to the nonpermissive nature of the adult CNS preventing axonal regeneration following injury...
  54. ncbi request reprint Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    J Neurol Sci 223:25-7. 2004
    ..This review provides information on data thus far present on the putative mechanisms of action of mitoxantrone in the immunopathogenesis of this disabling disease...
  55. ncbi request reprint Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine Universitat, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Trends Pharmacol Sci 24:131-8. 2003
    ..Second, there is evidence that axonal loss, rather than demyelination, underlies the progression of MS and, hence, constitutes a therapeutic target...
  56. ncbi request reprint Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases
    Bernd C Kieseier
    Departments of Neurology, Heinrich Heine University, Dusseldorf, Germany, and Karl Franzens University, Graz, Austria
    Arch Neurol 61:929-32. 2004
    ..Although interferon beta represents a mainstay in therapy for multiple sclerosis (MS), statins are considered a potential new approach in treating MS...
  57. ncbi request reprint Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University Moorenstrasse 5, 40225 Dusseldorf, Germany
    Exp Neurol 203:1-4. 2007
  58. ncbi request reprint [Cannabinoids in multiple sclerosis. Opportunity or hazard?]
    Oliver Neuhaus
    Neurologische Klinik, Heinrich Heine Universitat, Dusseldorf
    Nervenarzt 75:1022-6. 2004
    ..In this review, the results of the CAMS study are discussed in the context of previous trials, the putative mechanism of action of cannabinoids and their adverse event profile...
  59. ncbi request reprint ADAM-10 and ADAM-17 in the inflamed human CNS
    Bernd C Kieseier
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Dusseldorf, Germany
    Glia 42:398-405. 2003
    ..In contrast, under inflammatory conditions, ADAM-10, expressed by perivascular macrophages, and ADAM-17, expressed by invading T cells, may actively contribute to the pathogenesis of inflammatory disorders of the CNS...
  60. ncbi request reprint Mitoxantrone in multiple sclerosis
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Adv Neurol 98:293-302. 2006
  61. ncbi request reprint Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine Universitat, Moorenstr 5, 40225 Dusseldorf, Germany
    J Neuroimmunol 168:128-37. 2005
    ....
  62. ncbi request reprint Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    J Neurol Sci 259:27-37. 2007
    ..This article reviews data thus far present both on the pharmacokinetics as well as on the putative mechanisms of action of the interferon-betas, glatiramer acetate, and mitoxantrone in the immunopathogenesis of MS...
  63. ncbi request reprint Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis
    Bernhard Hemmer
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Lancet Neurol 4:403-12. 2005
    ..Strategies to assess and manage the long-term impact of neutralising antibodies will be outlined...
  64. ncbi request reprint Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis
    Olaf Stuve
    Department of Neurology and Institute of Diagnostic Radiology, Heinrich Heine University, Dusseldorf, Germany
    Arch Neurol 62:1620-3. 2005
    ..A limited effect of rituximab on B lymphocytes in the cerebrospinal fluid compartment of patients with primary progressive multiple sclerosis (MS) was recently reported...
  65. ncbi request reprint Therapeutic role of mitoxantrone in multiple sclerosis
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Pharmacol Ther 109:198-209. 2006
    ..The current knowledge of the putative mechanisms of action of the compound is discussed...
  66. ncbi request reprint Tissue mRNA expression in rat of newly described matrix metalloproteinases
    Fabian Bernal
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Dusseldorf, Germany
    Biol Res 38:267-71. 2005
    ..The present study highlights the differential distribution pattern of newly described MMPs among different tissues and underlines differences in the mRNA expression between different species...
  67. ncbi request reprint Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    J Neurol Sci 233:173-7. 2005
    ..Furthermore, the role of statins as potential pharmacotherapy for MS is discussed in the context of the mechanisms of approved immunotherapies in MS, namely IFN-beta and glatiramer acetate (GA)...
  68. ncbi request reprint Immunopathogenesis and immunotherapy of multiple sclerosis
    Bernhard Hemmer
    Neuroimmunology Group, Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Nat Clin Pract Neurol 2:201-11. 2006
    ..Here, we review current knowledge of the immunopathogenesis of MS and corresponding animal models of disease, and discuss new immunointerventional treatment strategies based on changing pathogenetic concepts...
  69. ncbi request reprint Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice
    Michael Schroeter
    Department of Neurology, Heinrich Heine University Dusseldorf, Germany
    Brain 129:1426-37. 2006
    ..Neuroprotective and anti-inflammatory effects of OPN may be relevant for a variety of neurological disease conditions...
  70. ncbi request reprint Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    J Neuropathol Exp Neurol 66:305-12. 2007
    ....
  71. ncbi request reprint Bilateral medullary pyramid infarction
    Philipp Zickler
    Department of Neurology, Heinrich Heine University Dusseldorf, Moorenstr 5, D 40225 Dusseldorf, Germany
    Neurology 64:1801. 2005
  72. ncbi request reprint Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage
    Stefan Nessler
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Brain 130:2186-98. 2007
    ..Taken together, MRI of mouse EAE models with brain lesions provide new insights into lesion pathology and evolution and may prove useful for the in vivo assessment of new therapeutic strategies in MS...
  73. ncbi request reprint Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy
    Hubertus Köller
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Curr Opin Neurol 18:273-8. 2005
    ..This review covers the growing literature of the past years that deals with the pathogenesis, diagnostic criteria and treatment of CIDP...
  74. ncbi request reprint Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    CNS Drugs 19:833-41. 2005
    ....
  75. ncbi request reprint Acute disseminated encephalomyelitis: an acute hit against the brain
    Til Menge
    Department of Neurology, Heinrich Heine University of Dusseldorf, Germany
    Curr Opin Neurol 20:247-54. 2007
    ..ADEM is a para- or postinfectious autoimmune demyelinating disease of the central nervous system and has been considered a monophasic disease. The highest incidence of ADEM is observed during childhood...
  76. ncbi request reprint Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis
    Oliver Neuhaus
    Heinrich Heine University, Department of Neurology, Dusseldorf, Germany
    Expert Rev Neurother 7:547-56. 2007
    ..In this review, we discuss the backgrounds, mechanisms of action and future perspectives of atorvastatin and simvastatin as putative future treatment options in MS...
  77. ncbi request reprint CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system
    Stefan Kastenbauer
    Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
    J Neuroimmunol 137:210-7. 2003
    ..controls...
  78. ncbi request reprint New concepts in the immunopathogenesis of multiple sclerosis
    Bernhard Hemmer
    Department of Neurology, Philipps Universitat, Marburg 35033, Germany
    Nat Rev Neurosci 3:291-301. 2002
  79. ncbi request reprint Immune-mediated neuropathies
    Reinhard Kiefer
    Department of Neurology, Universitatsklinikum Munster, D 48129 Munster, Germany
    Adv Neurol 88:111-31. 2002
  80. ncbi request reprint Therapeutic strategies in the Guillain-Barré syndrome
    Bernd C Kieseier
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Semin Neurol 23:159-68. 2003
    ..This review will address the rationale for immunotherapy in GBS based on experimental and immunologic studies of the pathogenesis of this disease...
  81. ncbi request reprint Are statins a treatment option for multiple sclerosis?
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Lancet Neurol 3:369-71. 2004
    ..Thus, identifying new effective therapeutic options with few side-effects is highly desirable...
  82. ncbi request reprint Interleukin 23 in acute inflammatory demyelination of the peripheral nerve
    Wei Hu
    Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich Heine University, Dusseldorf, Germany
    Arch Neurol 63:858-64. 2006
    ..Recent evidence suggests that IL-23 rather than IL-12 is critically involved in the pathogenesis of various immune-mediated disorders...
  83. ncbi request reprint Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
    Sabine Cepok
    Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
    Brain 128:1667-76. 2005
    ..This study identifies short-lived plasma blasts as the main effector B cell population involved in ongoing active inflammation in multiple sclerosis patients...
  84. ncbi request reprint Remyelinating strategies for the treatment of multiple sclerosis
    Martin Stangel
    Department of Neurology, Medical School Hannover OE 7210, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Prog Neurobiol 68:361-76. 2002
    ..In this review, we describe the current views on oligodendrocyte biology, myelination and remyelination, and focus on recent developments leading to reconstructing, remyelinating strategies in MS...
  85. ncbi request reprint Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders
    Helmar C Lehmann
    Department of Neurology, Heinrich Heine University of Dusseldorf, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Arch Neurol 63:1066-71. 2006
    ..Myasthenia gravis and Lambert-Eaton syndrome represent neuromuscular disorders where plasmapheresis might be of potential efficacy...
  86. ncbi request reprint The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies
    Thomas Dehmel
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany
    Neurobiol Dis 25:665-74. 2007
    ..Our results suggest that certain ADAMs are expressed by specific cell populations during the genesis of immune-mediated diseases of human muscle...
  87. pmc Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis
    Dun Zhou
    Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Proc Natl Acad Sci U S A 103:19057-62. 2006
    ..Overall these findings suggest a pathogenic antibody response to native MOG in a subgroup of MS patients...
  88. ncbi request reprint Multiple paradigm shifts in multiple sclerosis
    Bernd C Kieseier
    Curr Opin Neurol 16:247-52. 2003
    ..The present article reviews the currently ongoing scientific debate of our changing views on the pathogenesis of multiple sclerosis and the therapeutic strategies currently available for multiple sclerosis...
  89. ncbi request reprint Biologic role of interferon beta in multiple sclerosis
    Alfons Billiau
    Rega Institute, University of Leuven, Leuven, Belgium
    J Neurol 251:II10-4. 2004
    ..The relative importance of each of these actions is presently unknown, and still other actions of IFNbeta may be at play. The possibility that therapeutic IFNbeta compensates for a lack of endogenous IFNbeta production is discussed...
  90. ncbi request reprint Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis
    Bettina Schreiner
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    J Neuroimmunol 155:172-82. 2004
    ..IFN-beta up-regulates B7-H1 in vitro and in MS patients in vivo and might represent a novel mechanism how IFN-beta acts as a negative modulator on APC T-cell interactions in the periphery...
  91. ncbi request reprint Autoimmunity and inflammation in the peripheral nervous system
    Hugh Willison
    Dept of Neurology, University of Glasgow, UK
    Trends Neurosci 25:127-9. 2002
    ..Peripheral Nerve Society Biennial Meeting, organized in conjunction with the Austrian Federal Ministry of Education, Research and Culture, held at Telfs, Tyrol, Austria from 8-12 September 2001...
  92. doi request reprint Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial
    F Fazekas
    Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
    Neurology 71:265-71. 2008
    ..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety...
  93. doi request reprint Interferon beta in multiple sclerosis: predicting response at an early stage
    Joep Killestein
    Department of Neurology, VU Medical Centre Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:616-7. 2008
  94. ncbi request reprint Pharmacological treatment of early multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
    Drugs 68:73-83. 2008
    ....
  95. ncbi request reprint Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b
    Chris Polman
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Neurol 255:480-7. 2008
    ..The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions...
  96. ncbi request reprint Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
    Ludwig Kappos
    Neurology and Department of Research, University Hospital, Basel, Switzerland
    Lancet 370:389-97. 2007
    ..Our aim was to determine whether early initiation of treatment with interferon beta prevents development of confirmed disability in MS...